I’ve been challenged on the idea of whether or not Mylan is a monopoly, if so, what caused it, and how many competing solutions could exist in this relatively small market. I claim they are not, because alternatives exist. Other say they are a monopoly because there is not a generic EpiPen(r).
I’ve been told Europe has thriving competition in the autoinjector market and supports EIGHT different solutions. I’ll get back to this point later, but I did uncover two important developments in Europe that we aren’t seeing here in the US.
- The newer models are being offered in an additional dose of 0.5 in addition to 0.3 and 0.15. The new dose supports a higher body weight patient.
- There have been research results on needle length and one of the newer injectors addresses these new findings.
I have no idea about the state of regulation over there, but here are the claimed EIGHT other autoinjectors I found on the internet: